Roche bid to recycle Gazyva for lupus nephritis wins FDA breakthrough tag
Roche has won the U.S. Food and Drug Administration's breakthrough therapy tag for its drug Gazyva in lupus nephritis, the Swiss drugmaker said on Wednesday, boosting its efforts to recycle the 2013-approved lymphoma medicine for new indications. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Roche bid to recycle Gayzva for lupus nephritis wins FDA breakthrough tag
Roche has won the U.S. Food and Drug Administration's breakthrough therapy tag for its drug Gazyva in lupus nephritis, the Swiss drugmaker said on Wednesday, boosting its efforts to recycle the 2013-approved lymphoma medicine for new indications. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
FDA grants Breakthrough Therapy Designation for Roche ’s Gazyva (obinutuzumab) in Lupus Nephritis
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva ® (obinutuzumab) for adults with lupus nephritis. (Source: Roche Media News)
Source: Roche Media News - September 18, 2019 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Roche ’s Gazyva (obinutuzumab) in Lupus Nephritis
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva ® (obinutuzumab) for adults with lupus nephritis. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2019 Category: Pharmaceuticals Source Type: news
Cyclosporine benefits patients through more rapid remission of proteinuria in lupus nephritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest maintenance therapy with cyclosporine (CYA) results in more rapid remission of proteinuria compared to mycophenolate mofetil (MMF) or azathioprine (AZA) in patients with lupus nephritis. The efficacy of CYA, MMF and AZA in obtaining and maintaining remission of lupus nephritis (LN) is comparable over the long term. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news
Roche ’s Gazyva (obinutuzumab) delivers positive topline results for phase II lupus nephritis study
Roche today announced positive topline results for NOBILITY, a phase II clinical trial investigating the safety and efficacy of Gazyva ® (obinutuzumab) for adults with proliferative lupus nephritis. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2019 Category: Pharmaceuticals Source Type: news
Podcast: Immunosuppressive treatment for people with proliferative lupus nephritis
Systemic lupus erythematosus, or SLE, is an autoimmune disease that can affect any part of the body. About half the people with it develop lupus nephritis. In the June 2018 update of their Cochrane Review, David Tunnicliffe from the Centre for Kidney Research in the Children ’s Hospital at Westmead and the University of Sydney’s School of Public Health in Australia and colleagues brought together the studies that have tested a range of treatments." Lupus nephritis is a serious condition, leading to end-stage kidney disease in 15% of patients after 10 years. It mainly affects women of child-bearing age, and is more comm...
Source: Cochrane News and Events - May 30, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Researchers developing early detection, home monitoring tests for lupus nephritis
(University of Houston) With $5 million in grants from the National Institutes of Health (NIH), two University of Houston biomedical researchers are transforming the way lupus is managed, putting biomarkers in the hands of patients to monitor their own disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 2, 2019 Category: Biology Source Type: news
Peptide shows promise for protecting kidneys from nephritis
(Medical College of Georgia at Augusta University) A synthetic peptide appears to directly disrupt the destructive inflammation that occurs in nephritis, enabling the kidneys to better recover and maintain their important functions, investigators report. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2019 Category: International Medicine & Public Health Source Type: news
Low-Income SLE Patients at High Risk for Fracture (CME/CE)
(MedPage Today) -- Fracture risk was about 2.5-fold higher in this SLE subgroup with nephritis versus non-SLE patients (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 8, 2019 Category: Endocrinology Source Type: news
Nephrotic Syndrome: A Hindrance to Lupus Treatment?
(MedPage Today) -- In patients with lupus nephritis, lower renal response seen at 1 year (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2019 Category: Primary Care Source Type: news
Kidney Transplant Boosts Survival in Lupus Nephritis Kidney Transplant Boosts Survival in Lupus Nephritis
Kidney transplantation is associated with a survival benefit for patients with lupus nephritis and end-stage renal disease (LN-ESRD), researchers have found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Renal Transplant Improves Survival in ESRD Due to Lupus
WEDNESDAY, Jan. 23, 2019 -- For patients with end-stage renal disease (ESRD) due to lupus nephritis (LN), renal transplant is associated with a survival benefit, according to a study published online Jan. 22 in the Annals of Internal Medicine.
April... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 23, 2019 Category: Pharmaceuticals Source Type: news
Voclosporin Effective in Lupus Nephritis
(MedPage Today) -- Results from AURA-LV trial in patients with active disease (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 24, 2018 Category: Primary Care Source Type: news
Recurrent Post-Transplant Lupus Nephritis Declining
(MedPage Today) -- Single-center study credits improvements in immunosuppression (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 23, 2018 Category: Rheumatology Source Type: news
